Novartis Adds Patch Formulation To Exelon Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
Exelon Patch minimizes gastrointestinal side effects seen with the oral form of the cholinesterase inhibitor, Novartis says.
You may also be interested in...
Novartis Exelon Promotion Cited By FDA For Unsubstantiated Superiority Claims To Aricept
Professional file card for the Alzheimer's medication is misleading because it is based on an inadequate study, FDA warning letter says.
Novartis Exelon Promotion Cited By FDA For Unsubstantiated Superiority Claims To Aricept
Professional file card for the Alzheimer's medication is misleading because it is based on an inadequate study, FDA warning letter says.
Novartis To Submit Exelon Patch By Year-End
Novartis plans to submit a transdermal patch formulation of its Alzheimer's disease therapy Exelon (rivastigmine) by year-end, the firm said July 19